D N Mendhekar, R C Jiloha. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » AdultAnti-Anxiety Agents/administration & dosageAntiparkinson Agents/administration & dosageAntipsychotic Agents/adverse effectsBromocriptine/administration & dosageClozapine/adverse effectsCreatine Kinase/bloodCreatine Kinase/drug effectsDose-Response Relationship, DrugElectroconvulsive Therapy/methodsHaloperidol/adverse effectsHumansLorazepam/administration & dosageMaleNeuroleptic Malignant Syndrome/complicationsNeuroleptic Malignant Syndrome/drug therapyNeuroleptic Malignant Syndrome/psychologyPsychotic Disorders/complicationsPsychotic Disorders/drug therapySchizophrenia/drug therapySubstance Withdrawal Syndrome/complicationsSubstance Withdrawal Syndrome/drug therapySubstance Withdrawal Syndrome/psychology
Substances： See more » Anti-Anxiety AgentsAntiparkinson AgentsAntipsychotic AgentsBromocriptineCreatine KinaseClozapineHaloperidolLorazepam
Year: 2005 PMID： 16168023 DOI： 10.1111/j.1440-1614.2005.01705_2.x
Source DB: PubMed Journal: Aust N Z J Psychiatry ISSN： 0004-8674 Impact factor: 5.744